Health News Releases

  • Today May 19
August 03, 2017 13:45
Takeda Reports 1st Quarter FY2017 Results
Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth of 6.6% led by Takeda's Growth Drivers · Underlying Revenue grew +6.6% with growth across all regions (U.S. +13.5%,
August 02, 2017 14:55
Graminex L.L.C. Receives NNHPD Health Canada Approval for PollenAid® and Prostanex®
Graminex® LLC, producer of Graminex® Flower Pollen Extracts™, receives Health Canada Approval under the Natural and Non-prescription Health Products Directorate (NNHPD) for its PollenAid® and Prostane
August 01, 2017 13:25
Study Compares Performance of Masimo Acoustic Respiration Rate (RRa®) and Nellcor Plethysmographic Respiration Rate in Volunteers
Masimo (NASDAQ: MASI) announced today that researchers at the Tokyo Women’s Medical University, Department of Anesthesiology, in Japan have published a study investigating the measurement of respirati
July 28, 2017 10:30
Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®
Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable wi
July 28, 2017 09:40
Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV
Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommendin
July 24, 2017 18:10
Data Published in The Lancet Shows High Efficacy at 96 Weeks for First Investigational Two-Drug, Long-Acting Injectable HIV Regimen
Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced that a regimen of two investigational long-acting, injectable formulations of HI
July 24, 2017 18:05
Johnson & Johnson Announces Encouraging First-in-Human Clinical Data for Investigational HIV Preventive Vaccine
Johnson & Johnson today announced encouraging first-in-human clinical data for an investigational HIV-1 vaccine regimen in development at its Janssen Pharmaceutical Companies. In an oral presentation
July 24, 2017 17:55
People with idiopathic pulmonary fibrosis (IPF) reveal high burden of disease in new survey
New results from a global survey supported by Boehringer Ingelheim[1] reveal the emotional and practical challenges facing people with idiopathic pulmonary fibrosis (IPF). Patients are impacted by fee
July 24, 2017 09:00
Mannatech Korea Introduces the Most Advanced Ginseng Supplement in the World
Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, has launched GinMAX™ tablets in its Korea market. GinMAX is a powe
July 21, 2017 13:45
Masimo Announces CE Marking of Noninvasive RPVi™, a rainbow® Multi-Wavelength Index of Pleth Variability
Masimo (NASDAQ: MASI) announced today the CE marking of RPVi™, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during one or more respiratory cycles.
July 17, 2017 11:45
PSMF Convenes the International Patient Safety Community for its 2017 Midyear Planning Meeting at Inova Center for Personalized Health
The Patient Safety Movement Foundation (PSMF) brought together over 100 medical care providers, hospital administrators, and patient safety experts and advocates to discuss ongoing challenges and refi
July 17, 2017 09:00
Mannatech Korea Makes the Morning Healthier with New Nutrient-Rich Coffee
Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, recently launched the world’s most complete coffee, GlycoCafé™, to
July 12, 2017 17:30
Octapharma Symposium At ISTH Berlin Supports Progress in Lifelong Treatment of High-Risk Patients With Von Willebrand Disease (VWD) and haemophilia A
Octapharma is pleased to announce the success of yesterday’s symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress held in Berlin, Germany. As platinum sponsors of the c
July 11, 2017 18:40
Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations
Boehringer Ingelheim today announced final results from RE-VERSE AD™.[1,2] The study shows that Praxbind® (idarucizumab) was able to immediately and completely reverse the anticoagulant effect of Prad
July 11, 2017 13:50
ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data in previously untreated patients and demonstrates real-life value of personalised prophylaxis for Haemophilia A
Octapharma is playing a prominent role this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin, Germany. As a platinum sponsor of the congress, Octapharma’s acti
July 11, 2017 13:20
Masimo Announces CE Marking of rainbow® Super Sensor
Masimo (NASDAQ: MASI) announced today the CE marking of the rainbow® Super DCI®-mini sensor, a reusable spot-check sensor that features Masimo SET® Measure-through Motion and Low Perfusion™ pulse oxim
July 07, 2017 14:40
Octapharma Activities Prominent at the Upcoming 2017 ISTH Congress in Berlin, Germany
Octapharma today announced that it will be actively involved in a wide range of activities at this year’s International Society on Thrombosis and Haemostasis (ISTH) Congress. The Congress will be held
Yang In-Chul, CEO of Solmedix Co., Ltd and Santhosh Kumaraswamy, President of Mobiuso LLC
July 07, 2017 11:00
Solmedix and Mobiuso sign MOU to develop the MOSAIC Platform Software for innovative medical device
Solmedix Co., Ltd announced that Solmedix (CEO Yang In-chul, Seoul, Korea) and Mobiuso LLC (President Santhosh Kumaraswamy, New York, United State) signed an MOU for joint development of software and
July 06, 2017 10:55
Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers
Celgene Corporation (NASDAQ:CELG) and BeiGene, Ltd. (NASDAQ:BGNE) entered into a strategic collaboration to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 (PD
July 03, 2017 16:40
Ferring Appoints Lars Peter Brunse to Executive Board
Ferring Pharmaceuticals announced today that Lars Peter Brunse has been appointed Executive Vice President and Chief Production Officer, and made a member of the Ferring Executive Board, effective imm
June 29, 2017 20:10
‘More than Systemic Sclerosis: The Inside Story’ - patients reveal the unseen impact of lung fibrosis
‘More than Systemic Sclerosis: The Inside Story’ launches today to mark World Scleroderma Day. This global initiative highlights the importance of understanding the ‘inside story’ of each individual l
June 28, 2017 13:30
Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the Phase 3 ECHELON-1 clinical trial met its primary endpoint of a statistically signifi
June 26, 2017 09:55
Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that data from two Phase 1/2 clinical trials evaluating NINLARO™ (ixazomib) in patients with newly diagnosed multiple myeloma will be
June 22, 2017 17:15
Bionext Launches Biosight: an Online Platform That Will Revolutionize Pharmaceutical Research
Bionext, a bioinformatics company, announces today the launch of BioSight, an online bio-simulation platform designed for efficient identification of possible side effects of potential drug treatments
June 21, 2017 18:05
New data reveal high rates of stroke history in asymptomatic atrial fibrillation patients
Boehringer Ingelheim today announced findings from GLORIA™-AF which show that people with non-valvular atrial fibrillation (AF) with few or no symptoms are more likely to have had a stroke prior to AF
25 per page50 per page75 per page100 per page